Sales Goals and Performance - The company has set internal sales targets for 2026, which will not be disclosed externally, and is optimistic about achieving good performance based on refined operations in 2025 [2] - The sales ratio of online to offline channels has improved from 80:20 in the 2025 semi-annual report, with further details to be revealed in the 2025 annual report [2][3] - The company reported good performance during the 3.8 promotional event, aligning with expectations, and aims to enhance sales through active participation in platform activities [3] Product Development and Innovation - The company has a robust pipeline of new products for 2026, including various forms such as dressings, masks, lotions, creams, and serums, with specifics to be confirmed based on actual launches [3] - The R&D team has expanded significantly compared to early 2025, with improvements in the educational background of its members [3] Profitability and Business Strategy - The company plans to strengthen its offline business in 2026, which has a higher net profit margin compared to online sales, and is confident in achieving better overall profitability [3] - The company is considering stock incentive plans but has not set a specific timeline for implementation, with future updates to be disclosed in accordance with regulatory requirements [3] Dividend and Financial Planning - The dividend plan for the current year has not yet been determined, and stakeholders are advised to monitor announcements scheduled for April 23, 2026 [3] General Information - The investor relations activity did not involve any major information that needs to be disclosed [3]

Group 1: Channel Optimization and Sales Outlook - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining strong offline sales efforts [3] Group 2: New Product Planning - The company has a well-prepared new product plan for 2026, covering various product forms including dressings, masks, lotions, creams, and serums, with actual launches to be confirmed later [3] Group 3: Non-Patch Product Revenue Trends - Since the establishment of the Shanghai R&D center, the company has increased its focus on non-patch products, leading to a rising revenue share from these products [3] Group 4: OTC Channel Development - The current coverage of the OTC channel is relatively low, indicating significant expansion potential; the company plans to increase personnel in this area to improve pharmacy coverage [3] Group 5: Sales Performance and Promotions - Sales during the 38 Festival are meeting expectations, with a focus on daily sales complemented by promotional activities to enhance overall performance [3] Group 6: Product Development Progress - Clinical trials for the recombinant type III humanized collagen freeze-dried fibers have been completed, with submission materials being prepared; other products are at various stages of clinical trials [3] Group 7: Shareholder and Acquisition Plans - The chairman has no current plans to reduce his shareholding, and while the company is monitoring potential acquisition targets, there are no suitable candidates at this time [3] Group 8: Dividend Considerations - The dividend proposal for the fiscal year 2025 has not yet been determined, and stakeholders are encouraged to stay updated [4]

Group 1: Sales and Market Strategy - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining offline sales efforts [3] - The company has increased personnel in the OTC channel to improve pharmacy coverage, indicating significant growth potential in this area [3] Group 2: Product Development and Innovation - The company has a well-prepared product plan for 2026, including various new product forms such as dressings, masks, lotions, creams, and serums [3] - Since the establishment of the Shanghai R&D center, the revenue share of non-patch products has been increasing due to ongoing R&D efforts [3] - Progress on three types of medical devices includes completion of clinical trials for recombinant type III humanized collagen freeze-dried fibers and initiation of clinical trials for other products [3] Group 3: Financial and Corporate Governance - The chairman has no plans to reduce his shareholding in the company, ensuring stability in corporate governance [3] - The dividend plan for the fiscal year 2025 has not yet been determined, pending further developments [4] - The company is monitoring potential acquisition projects but currently has no suitable targets [3]

Group 1 - The company Aishalon (920050.SH) has been deeply engaged in the medical device industry for over 20 years, with products exported to multiple countries [1] - The medical protective equipment sector has a broad development outlook, and the company's products have passed three international certifications [1] - The average PE ratio of comparable companies is 22.8X for 2024 [1]

Group 1: Medline (MDLN) - Medline opened at $35 per share, a 20.69% increase from the offering price, and closed at $41, marking a 41.38% rise with a total market capitalization of $75.563 billion [2][4] - The company issued 216 million shares at $29 each, raising $6.265 billion, with plans to use the funds for debt repayment and general corporate purposes [4] - Medline is a leading global manufacturer and distributor of medical supplies, producing hundreds of thousands of consumable medical products including surgical gloves, gowns, dressings, and surgical packs [4] Group 2: Andersen (ANDG) - Andersen opened at $21 per share, a 31.25% increase from the offering price, and closed at $23.5, reflecting a 46.88% rise with a total market capitalization of $2.569 billion [5][7] - The company issued 11 million shares at $16 each, raising $176 million, with plans to invest in technology, infrastructure, training, and potential strategic acquisitions [7] - Andersen provides independent tax, valuation, and financial consulting services to individuals, family offices, businesses, and institutional clients, having served 11,900 clients as of September 30, 2025 [7] Group 3: SPACs - Churchill Capital XI (CCXIU) raised $360 million, while Iron Horse Acquisition II (IRHOU) raised $200 million [8] - Churchill Capital XI, initiated by Michael Klein, aims to target companies with stable revenues and strong management teams [8] - Iron Horse Acquisition II, led by Jose Bengochea, focuses on the media and entertainment industry, particularly in music, animation, and artificial intelligence [8]

Core Viewpoint - Medline Inc., a major U.S. healthcare company focused on medical supplies, is seeking to raise up to $5.37 billion through an IPO, potentially becoming the largest private equity-backed IPO in history and the largest U.S. IPO of the year [1][2]. Company Overview - Medline specializes in the production and distribution of medical supplies such as gloves, isolation gowns, surgical apparel, and examination tables for hospitals and healthcare professionals [4]. - The company was privatized in 2021 in a $34 billion deal led by private equity firms Blackstone, Carlyle Group, and Hellman & Friedman, marking one of the largest leveraged buyouts in financial history [4]. - Medline has a history dating back to 1910 and is one of the largest private manufacturers and distributors of medical and surgical supplies in North America and globally, with annual sales exceeding $20 billion [4]. IPO Details - The company plans to issue 179 million shares at a price range of $26 to $30 per share, with a maximum valuation of $55.3 billion [1][2]. - If priced at the top of the range, the IPO would raise $5.37 billion, surpassing the previous largest U.S. IPO of $1.75 billion by Venture Global Inc. in January [2]. - The IPO filing was submitted after a prolonged U.S. government shutdown that disrupted many companies' IPO plans, with Medline initially expecting to go public in November [2]. Financial Performance - For the nine months ending September 27, Medline reported a net profit of approximately $977 million and total revenue of about $20.6 billion, compared to a net profit of $911 million and revenue of approximately $18.7 billion in the same period the previous year [3]. Investment and Shareholder Structure - The company has secured approximately $2.35 billion in commitments from cornerstone investors, including Baillie Gifford, Capital Group, and Morgan Stanley's Counterpoint Global [5]. - Following the IPO, the Mills family will retain 17.8% of the voting rights, while Blackstone, Carlyle, and Hellman & Friedman will each hold 18% [7]. Market Context - The total amount raised from U.S. IPOs this year (excluding blank-check companies) is approximately $38.7 billion, which is expected to remain below the pre-pandemic average of nearly $50 billion per year [6]. - Major investment banks, including Goldman Sachs, Morgan Stanley, Bank of America, and JPMorgan, are involved in the IPO process, with the expected pricing to occur after market close on December 16 [8].